Bolt Biotherapeutics Inc logo

BOLT - Bolt Biotherapeutics Inc Share Price

$32.17 0.5  1.6%

Last Trade - 03/03/21

Sector
Healthcare
Size
Large Cap
Market Cap £3.70bn
Enterprise Value £3.75bn
Revenue £212k
Position in Universe 1345th / 6642
Bullish
Bearish
Unlock BOLT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.22
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BoltBiotherapeutics Inc revenues increased 54% to $231K. Netloss increased 41% to $29.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and d increase of 36% to $25.1M (expense), Generalan increase from $3M to $6.6M (expense), Stock-basedCompensation in SGA increase from $76K to $431K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BOLT Revenue Unlock BOLT Revenue

Net Income

BOLT Net Income Unlock BOLT Revenue

Normalised EPS

BOLT Normalised EPS Unlock BOLT Revenue

PE Ratio Range

BOLT PE Ratio Range Unlock BOLT Revenue

Dividend Yield Range

BOLT Dividend Yield Range Unlock BOLT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BOLT EPS Forecasts Unlock BOLT Revenue
Profile Summary

Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 22, 2015
No. of Shareholders: n/a
No. of Employees: 63
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 160,574,517
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BOLT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BOLT
Upcoming Events for BOLT
Frequently Asked Questions for Bolt Biotherapeutics Inc
What is the Bolt Biotherapeutics Inc share price?

As of 03/03/21, shares in Bolt Biotherapeutics Inc are trading at $32.17, giving the company a market capitalisation of £3.70bn. This share price information is delayed by 15 minutes.

How has the Bolt Biotherapeutics Inc share price performed this year?

Shares in Bolt Biotherapeutics Inc are currently trading at $32.17 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bolt Biotherapeutics Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Bolt Biotherapeutics Inc?

Of the analysts with advisory recommendations for Bolt Biotherapeutics Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Bolt Biotherapeutics Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Bolt Biotherapeutics Inc next release its financial results?

Bolt Biotherapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Bolt Biotherapeutics Inc dividend yield?

Bolt Biotherapeutics Inc does not currently pay a dividend.

Does Bolt Biotherapeutics Inc pay a dividend?

Bolt Biotherapeutics Inc does not currently pay a dividend.

When does Bolt Biotherapeutics Inc next pay dividends?

Bolt Biotherapeutics Inc does not currently pay a dividend.

How do I buy Bolt Biotherapeutics Inc shares?

To buy shares in Bolt Biotherapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bolt Biotherapeutics Inc?

Shares in Bolt Biotherapeutics Inc are currently trading at $32.17, giving the company a market capitalisation of £3.70bn.

Where are Bolt Biotherapeutics Inc shares listed? Where are Bolt Biotherapeutics Inc shares listed?

Here are the trading details for Bolt Biotherapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BOLT
What kind of share is Bolt Biotherapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Bolt Biotherapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bolt Biotherapeutics Inc share price forecast 2021?

We were not able to load any forecast data for Bolt Biotherapeutics Inc.

How can I tell whether the Bolt Biotherapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bolt Biotherapeutics Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $32.17, shares in Bolt Biotherapeutics Inc are trading at 1.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bolt Biotherapeutics Inc PE Ratio?

We were not able to find PE ratio data for Bolt Biotherapeutics Inc.

Who are the key directors of Bolt Biotherapeutics Inc?

Bolt Biotherapeutics Inc's management team is headed by:

Peter Moldt - CHM
Randall Schatzman - CEO
William Quinn - CFO
David Dornan - SVP
Michael Alonso - VPR
Who are the major shareholders of Bolt Biotherapeutics Inc?

Here are the top five shareholders of Bolt Biotherapeutics Inc based on the size of their shareholding:

Novo Holdings A/S Venture Capital
Percentage owned: 13.05% (4.50m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 11.21% (3.87m shares)
Citadel Advisors LLC Hedge Fund
Percentage owned: 8.52% (2.94m shares)
Sofinnova Investments, Inc Venture Capital
Percentage owned: 7.98% (2.75m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 6.89% (2.38m shares)
Similar to BOLT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.